

## About the Author

Dr Mugisha is a medical scientist working at the Uganda Research Unit of the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine. During COVID-19, he has led surveillance activity in the unit's General Population Cohort in southwestern Uganda. His research interests are primarily on the health and social issues affecting older people in low- and middle-income countries.

## References

1. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. *Nat Med*. 2022; 28(9):1785-1790. <https://doi.org/10.1038/s41591-022-01911-2>. PMID: 35760080
2. Kimura I, Yamasoba D, Tamura T, Nao N, Oda Y, Mitoma S, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. *Cell*. 2022;185(21):3992-4007.e16. ISSN 0092-8674 <https://doi.org/10.1016/j.cell.2022.09.018>.
3. Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. *Nat Commun*. 2022;13(1):4686. <https://doi.org/10.1038/s41467-022-32396-9>. Erratum in: *Nat Commun*. 2022 Oct 13;13(1):6057. PMID: 35948557
4. Wang Q, Guo Y, Iketani S, Li Z, Mohri H, Wang M, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. *Nature*. 2022;608:603-608. <https://doi.org/10.1038/s41586-022-05053-w>
5. Tuekprakhon A, Nutalai R, Djikajite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et al.; OPTIC Consortium; ISARIC4C Consortium. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell*. 2022;185:2422-2433.e13.
6. Harris JR, Owusu D, O'Laughlin K, Cohen AL, Ben Hamida A, Patel JC, et al. SARS-CoV-2 breakthrough infections among US Embassy staff members, Uganda, May-June 2021 [cited 2022 Jun 12]. *Emerg Infect Dis*. 2022;28:1279-80. <https://doi.org/10.3201/eid2806.220427>
7. Asiki G, Murphy G, Nakiyingi-Miiró J, Seeley J, Nsubuga RN, Karabarinde A, et al.; GPC team. The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies [cited 2020 Mar 3]. *Int J Epidemiol*. 2013;42:129-41. <https://doi.org/10.1093/ije/dys234>
8. Cotten M, Bugembe DL, Kaleebu P, Phan MVT. Alternate primers for whole-genome SARS-CoV-2 sequencing. *Virus Evol*. 2021 Feb 4 [cited 2021 Mar 7]. <https://academic.oup.com/ve/advance-article/doi/10.1093/ve/veab006/6128533>
9. Aksamentov I, Roemer C, Hodcroft E, Neher R. Nextclade: clade assignment, mutation calling and quality control for viral genomes [cited 2022 Jun 13]. *J Open Source Softw*. 2021;6:3773. <https://doi.org/10.21105/joss.03773>
10. O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. *Virus Evol*. 2021;7:veab064. <https://doi.org/10.1093/ve/veab064>

Address for correspondence: Matthew Cotten, MRC/UVRI & LSHTM Uganda Research Unit, PO Box 49, Plot 51-59, Nakiwogo Road, Entebbe, Uganda; email: Matthew.Cotten@lshtm.ac.uk

## Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021

Stephanie J. Curtis,<sup>1</sup> Abdul W. Shah,<sup>1</sup> Ana Ratu, Donald J. Wilson, Philip C. Hill, Phil Hulcome, Cathy Gaylard, Daniel Faktaufon, Talica Cabemaiwai, Isireli Rabukawaqa, Tevita Qoriniasi, Akesh Narayan, Susana Nakalevu, Pablo Romakin, Jemesa Tudravu, James Fong,<sup>2</sup> Nick Walsh<sup>2</sup>

Author affiliations: National Critical Care and Trauma Response Centre, Darwin, Northern Territory, Australia (S.J. Curtis, C. Gaylard, N. Walsh); Ministry of Health and Medical Services, Suva, Fiji (A.W. Shah, D. Faktaufon, T. Cabemaiwai, I. Rabukawaqa, T. Qoriniasi, A. Narayan, S. Nakalevu, P. Romakin, J. Tudravu, J. Fong); Fiji National University, Suva (A. Ratu, D.J. Wilson, P.C. Hill); University of Otago, Dunedin, New Zealand (P.C. Hill); Fiji Program Support Facility, Suva (P. Hulcome)

DOI: <https://doi.org/10.3201/eid2901.221514>

During November–December 2021, we performed a SARS-CoV-2 seroprevalence survey in Central and Western Divisions of Fiji. A total of 539 participants 8–70 years of age were 95.5% (95% CI 93.4%–97.1%) seropositive, indicating high community levels of immunity. Seroprevalence studies can inform public health responses to emerging SARS-CoV-2 variants.

In Fiji, the SARS-CoV-2 Delta variant wave occurred in a largely unvaccinated and nonimmune population during April–November 2021 (1). A risk-based COVID-19 vaccine rollout strategy commenced in March 2021, and, by late November 2021, a total of 90.6% of persons  $\geq 18$  years of age had received 2 vaccine doses and 97.3% had received 1 dose (1). Because of the high vaccination coverage, the government of Fiji had planned to reopen international borders by early December 2021.

Serosurveillance is a fundamental component of public health response to disease. Estimating disease epidemiology, including population immunity, by using serosurveillance can inform government policy. In November 2021, no serosurveillance data were available from any Pacific Island country or territory, and data from this region remain sparse (2). To inform public health decisions on the safe opening

<sup>1</sup>These first authors contributed equally to this article.

<sup>2</sup>These senior authors contributed equally to this article.

of international borders, we performed a rapid operational estimate of SARS-CoV-2 seroprevalence in Central and Western Divisions of Fiji.

We conducted a single cross-sectional serosurvey during November 24–December 1, 2021. The study population comprised persons deemed at higher risk for SARS-CoV-2 infection who were 8–70 years of age and located in Central and Western Divisions of Fiji. Persons at higher risk of infection included those who worked in healthcare, tourism, hospitality, retail, transportation, and education industries and primary or secondary school students. We used convenience sampling through nonrandom selection of study participants. The government of Fiji identified recruitment sites for persons at high risk for COVID-19 and directly invited those sites to identify potential study participants. We aimed to recruit 550 participants, including at least 50 unvaccinated persons, who were a nationally representative sample of sex and age within the community (3).

Field teams were trained in data collection protocols that aligned with the World Health Organization UNITY protocol (4). We approached potential participants at recruitment sites and administered a

brief questionnaire (Appendix, <https://wwwnc.cdc.gov/EID/article/29/1/22-1514-App1.pdf>) and collected blood samples after informed consent was obtained. We tested serum samples for IgG against the receptor-binding domain of SARS-CoV-2 by using the SARS-CoV-2 Ab ELISA (Beijing Wantai Biologic, <https://www.ystwt.cn>), which has 96.7% sensitivity and 97.5% specificity across Alpha and Beta variants.

We merged questionnaire and laboratory data, summarized covariates, and estimated seroprevalence with 95% CIs. We performed analyses using R version 4.0.2 (The R Project for Statistical Computing, <https://www.r-project.org>). The Fiji National Human Research Ethics Committee reviewed all study materials and provided a letter of approval; however, formal ethics approval was not required.

We recruited 539 participants who were 30 ±14 years of age (mean ±SD); 47.3% (255/539) were male and 52.7% (284/539) female (Table). Most participants had received 2 doses of a COVID-19 vaccine (443/539, 82.2%), including 94.9% (463/488) of participants who were eligible for vaccination during the survey period. Overall seroprevalence was 95.5% (95% CI 93.4%–97.1%). Of those who had not received

**Table.** Participant characteristics from a rapid SARS-CoV-2 seroprevalence survey in Central and Western Divisions of Fiji, November–December 2021

Characteristics	No. (%) <sup>*</sup>	No. seropositive <sup>†</sup>	Seroprevalence, % (95% CI)
Total	539	515	95.5 (93.4–97.1)
Sex			
M	255 (47.3)	246	96.5 (93.2–98.3)
F	284 (52.7)	269	94.7 (91.3–97.0)
Age, years			
8–11	51 (9.5)	36	70.6 (56.0–82.1)
12–17	73 (13.5)	66	90.4 (80.7–95.7)
18–29	132 (24.5)	132	100 (96.5–100)
30–39	143 (26.5)	141	98.6 (94.5–99.8)
40–49	96 (17.8)	96	100 (95.2–100)
>50	44 (8.2)	44	100 (90.0–100)
Ethnicity			
I-Taukei	269 (49.9)	259	96.3 (93.1–98.1)
Fijian of Indian descent	249 (46.2)	236	94.8 (91.0–97.1)
Fijian of other descent	21 (3.9)	20	95.2 (74.1–99.8)
Occupation industry			
Healthcare worker	158 (29.3)	157	99.4 (96.0–99.9)
Student	142 (26.3)	120	84.5 (77.3–89.8)
Transportation	94 (17.4)	94	100 (95.1–100)
Hotel	69 (12.8)	69	100 (93.4–100)
Education	40 (7.4)	39	97.5 (85.7–99.9)
Hospitality	36 (6.7)	36	100 (88.0–100)
COVID-19 vaccine status			
None	76 (14.1)	58	76.3 (64.9–85.0)
1 dose	20 (3.7)	16	80.0 (55.7–93.4)
2 doses	443 (82.2)	441	99.5 (98.2–99.9)
Self-reported previous COVID-19			
No	410 (76.1)	387	94.4 (91.6–96.3)
Yes	117 (21.7)	117	100 (96.0–100)
Unknown	12 (2.2)	11	91.7 (59.7–99.6)

<sup>\*</sup>Percentage of total.

<sup>†</sup>Number seropositive for SARS-CoV-2.

a COVID-19 vaccine, 75% (58/76) were seropositive, including 70% (36/51) of children 8–11 years of age who were not eligible for vaccination during the survey period, indicating serum antibodies resulted from acquired infections.

We demonstrated a high level of immunity in participants  $\geq 18$  years of age in Central and Western Divisions of Fiji during late November and early December 2021. The results provided reassurance that international borders could open to fully vaccinated international travelers, without the necessity of previous hotel quarantine requirements, and relative safety of persons at higher risk for infection could be maintained. Our results highlighted a gap in pediatric vaccine coverage that included children 12–17 years of age who were eligible for vaccination during this investigation and were subsequently prioritized for vaccination by the government of Fiji.

The first limitation of our study is that direct extrapolation of the results to the general public is problematic because we conducted convenience sampling of the study population; however, the Central and Western Divisions account for about two thirds of the population of Fiji and were chosen because of resource availability. Second, our IgG measurements did not differentiate between immunity acquired by vaccination or infection or provide evidence of protection or population risk, particularly for severe COVID-19 (5). Hybrid immunity in our study population was likely high because of the recent national Delta variant outbreak and COVID-19 vaccination program (6). Third, our investigation occurred before the Omicron variant wave, which resulted in  $\approx 12,000$  notified COVID-19 cases during December 2021–February 2022 (2). However, the lower Omicron case notifications compared with the previous Delta wave of  $\approx 52,000$  cases support the likelihood that high population-level immunity attenuated illness from the highly transmissible Omicron variant when international borders reopened (7). Overall, further nationwide seroprevalence studies can inform the public health response as new COVID-19 variants emerge and demonstrate how population immunity might wane in the absence of continued COVID-19 vaccination efforts (8–10).

### Acknowledgments

We thank the Fiji Ministry of Health and Human Services, including the dedicated fieldwork team, Australia's Fiji Program Support Facility, and the Australian High Commission team in Fiji, Department of Foreign Affairs and Trade, for their contributions to this study, and Kerry Osborne for her help planning this initiative.

The seroprevalence survey was funded by the Australian Department of Foreign Affairs and Trade through the National Critical Care and Trauma Response Centre.

### About the Author

Ms. Curtis is an epidemiologist at the National Critical Care and Trauma Response Centre. Her primary interests are epidemiology of infectious diseases, disease outbreak management, and public health emergency response.

### References

1. Fiji Ministry of Health and Medical Services. COVID-19 update – 29-10-2021 [cited 2021 Nov 19]. <https://www.health.gov.fj/29-10-2021>
2. Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies. *PLoS Med.* 2022;19:e1004107. PubMed <https://doi.org/10.1371/journal.pmed.1004107>
3. Fiji Bureau of Statistics. 2017 Population and housing census – release 1 [cited 2021 Nov 19]. <https://www.statsfiji.gov.fj/index.php/census-2017/census-2017-release-1>
4. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection. 26 May 2020 [cited 2021 Nov 19]. <https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2>
5. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al.; Oxford COVID Vaccine Trial Group. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med.* 2021;27:2032–40. <https://doi.org/10.1038/s41591-021-01540-1>
6. Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. *Lancet Glob Health.* 2021;9:e598–609. [https://doi.org/10.1016/S2214-109X\(21\)00026-7](https://doi.org/10.1016/S2214-109X(21)00026-7)
7. Ito K, Piantham C, Nishiura H. Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark. *J Med Virol.* 2022;94:2265–8. <https://doi.org/10.1002/jmv.27560>
8. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance – VISION Network, 10 states, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:255–63. <https://doi.org/10.15585/mmwr.mm7107e2>
9. Abu-Raddad LJ, Chemaitelly H, Bertollini R; National Study Group for COVID-19 Vaccination. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. *N Engl J Med.* 2022;386:799–800. <https://doi.org/10.1056/NEJMc2117933>
10. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nat Med.* 2022;28:1063–71. <https://doi.org/10.1038/s41591-022-01753-y>

Address for correspondence: Stephanie J. Curtis, Royal Darwin Hospital, Rocklands Drive, Tiwi, Northern Territory, 0810, Australia; email: [stephanie.curtis@nt.gov.au](mailto:stephanie.curtis@nt.gov.au)

# Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021

## Appendix

We used the following participant questionnaire to conduct a rapid SARS-CoV-2 seroprevalence survey in Central and Western Divisions of Fiji during November 24–December 1, 2021.

Unique ID	
Date of interview	
Participant parent/guardian full name (if applicable)	
Participant full name	
Please take a photo and upload the informed consent form.	
Would you like a copy of the study results emailed to you?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Email or phone number	
Sex	<input type="checkbox"/> Male <input type="checkbox"/> Female
Date of birth	
Ethnicity	<input type="checkbox"/> I-Taukei <input type="checkbox"/> Fijian of Indian Descent <input type="checkbox"/> Fijian of Other Descent
Occupation industry	<input type="checkbox"/> Healthcare worker (clinical) <input type="checkbox"/> Healthcare worker (public health) <input type="checkbox"/> Healthcare worker (administrative) <input type="checkbox"/> Education <input type="checkbox"/> Student <input type="checkbox"/> Transport <input type="checkbox"/> Hospitality <input type="checkbox"/> Hotels

	<input type="checkbox"/> Other
Are you vaccinated against COVID-19?	<input type="checkbox"/> No <input type="checkbox"/> Yes, one dose <input type="checkbox"/> Yes, fully vaccinated (two doses) <input type="checkbox"/> Yes, fully vaccinated (three doses)
If yes to any of the above, what is the estimate date of most recent vaccine?	
What brand of vaccine did you receive?	<input type="checkbox"/> AstraZeneca <input type="checkbox"/> Moderna <input type="checkbox"/> Pfizer <input type="checkbox"/> Unknown <input type="checkbox"/> Other
If other, what vaccine brand?	
In the preceding one month, have you had any of the following symptoms suggestive of COVID-19?	For each tick either: Yes, No, Unknown <input type="checkbox"/> Fever ( $\geq 38$ °C) or history of fever <input type="checkbox"/> Sore throat <input type="checkbox"/> Runny nose (rhinorrhea) <input type="checkbox"/> Cough <input type="checkbox"/> Shortness of breath (dyspnea) <input type="checkbox"/> Other respiratory symptoms <input type="checkbox"/> Chills <input type="checkbox"/> Vomiting <input type="checkbox"/> Nausea <input type="checkbox"/> Diarrhea <input type="checkbox"/> Headache <input type="checkbox"/> Rash <input type="checkbox"/> Conjunctivitis <input type="checkbox"/> Muscle aches <input type="checkbox"/> Joint ache(myalgia) <input type="checkbox"/> Loss of appetite <input type="checkbox"/> Loss of smell (anosmia) <input type="checkbox"/> Loss of taste (ageusia) <input type="checkbox"/> Nose bleed <input type="checkbox"/> Fatigue <input type="checkbox"/> Seizures <input type="checkbox"/> Altered consciousness <input type="checkbox"/> Other neurological signs <input type="checkbox"/> Other symptoms
In the preceding six months, have you had any of the following symptoms suggestive of COVID-19?	For each tick either: Yes, No, Unknown <input type="checkbox"/> Fever ( $\geq 38$ °C) or history of fever <input type="checkbox"/> Sore throat <input type="checkbox"/> Runny nose (rhinorrhea)

	<input type="checkbox"/> Cough <input type="checkbox"/> Shortness of breath (dyspnea) <input type="checkbox"/> Other respiratory symptoms <input type="checkbox"/> Chills <input type="checkbox"/> Vomiting <input type="checkbox"/> Nausea <input type="checkbox"/> Diarrhea <input type="checkbox"/> Headache <input type="checkbox"/> Rash <input type="checkbox"/> Conjunctivitis <input type="checkbox"/> Muscle aches <input type="checkbox"/> Joint ache(myalgia) <input type="checkbox"/> Loss of appetite <input type="checkbox"/> Loss of smell (anosmia) <input type="checkbox"/> Loss of taste (ageusia) <input type="checkbox"/> Nose bleed <input type="checkbox"/> Fatigue <input type="checkbox"/> Seizures <input type="checkbox"/> Altered consciousness <input type="checkbox"/> Other neurological signs <input type="checkbox"/> Other symptoms
In 2021, have you been in contact with anyone who tested positive for COVID-19?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown
If yes to above, what was the estimated date of last contact?	
In 2021, did you live with anyone who tested positive for COVID-19?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown
If yes to above, what was the estimated date of last contact?	
In 2021, did you work with anyone who tested positive for COVID-19?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown
If yes to above, what was the estimated date of last contact?	
In 2021, did you test positive for COVID-19?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown

If yes to above, what month did you test positive?	<input type="checkbox"/> January <input type="checkbox"/> February <input type="checkbox"/> March <input type="checkbox"/> April <input type="checkbox"/> May <input type="checkbox"/> June <input type="checkbox"/> July <input type="checkbox"/> August <input type="checkbox"/> September <input type="checkbox"/> October <input type="checkbox"/> November <input type="checkbox"/> December
In what division was this participant recruited?	<input type="checkbox"/> Western <input type="checkbox"/> Central